Hematologic Oncology Update
Featuring one-on-one interviews conducted by Dr Neil Love, this series provides medical oncologists with access to an array of important perspectives and information on relevant advances in the treatment of hematologic cancer to facilitate optimal patient care.
Latest episodes
Apr 24, 2024 • 1h 5min
Oncology Today with Dr Neil Love: Key Presentations on Myeloproliferative Neoplasms from Recent Major Conferences
Dr Naveen Pemmaraju from The University of Texas MD Anderson Cancer Center in Houston discusses updated findings from ASH 2023 on management approaches for myelofibrosis and polycythemia vera.
Apr 12, 2024 • 1h 35min
Oncology Today with Dr Neil Love: Key Presentations on Chronic Lymphocytic Leukemia from Recent Major Conferences
Dr Bita Fakhri from Stanford University in Stanford, California, discusses recent updates from ASH 2023 for the management of chronic lymphocytic leukemia and Richter’s syndrome.
Mar 27, 2024 • 1h
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Lymphoma
Dr Andrew M Evens from the Rutgers Cancer Institute of New Jersey in New Brunswick and Dr Sonali M Smith from the University of Chicago in Illinois discuss clinical decision-making with numerous treatment strategies for lymphoma.
Mar 8, 2024 • 1h
Meet The Professor: Optimizing the Management of Myelofibrosis — Part 1 of a 2-Part Series
Dr Stephen T Oh from Washington University School of Medicine in St Louis, Missouri, discusses current and emerging monitoring and management strategies for myelofibrosis.
Feb 27, 2024 • 58min
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Chronic Lymphocytic Leukemia
Dr Lindsey Roeker from Memorial Sloan Kettering Cancer Center in New York, New York, and Dr Jeff Sharman of the US Oncology Network in Eugene, Oregon, discuss relevant datasets from 2023 on the management of chronic lymphocytic leukemia.
Jan 17, 2024 • 1h
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 3 of a 3-Part Series
Dr Richard M Stone from Dana-Farber Cancer Institute in Boston discusses the optimal selection and sequencing of systemic therapies for patients with acute myeloid leukemia and myelodysplastic syndromes.
Nov 10, 2023 • 1h 2min
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 2 of a 3-Part Series
Dr Gail J Roboz from Weill Cornell Medicine in New York discusses the optimal management of acute myeloid leukemia and myelodysplastic syndromes.
Oct 20, 2023 • 1h 2min
Meet The Professor: Optimizing the Management of Acute Myeloid Leukemia and Myelodysplastic Syndromes — Part 1 of a 3-Part Series
Dr Naval Daver from The University of Texas MD Anderson Cancer Center discusses optimizing the management of acute myeloid leukemia and myelodysplastic syndromes. Topics include the productivity of researchers in leukemia, the potential of checkpoint inhibitors, challenges of managing TP53 mutated disease, various drug therapies for AML and MDS, management of qtc prolongation, combination therapy, and the continuation of Van Aza treatment.
Oct 19, 2023 • 1h 2min
What Clinicians Want to Know About the Management of Relapsed/Refractory Mantle Cell Lymphoma
Dr Toby A Eyre and Dr Brad S Kahl discuss the management of relapsed/refractory mantle cell lymphoma, including treatment options like BTK inhibitors and CAR T-cell therapy, ongoing clinical trials, toxicity analysis of BTK inhibitors, use of MRD in clinical practice, combination treatment, and side effect management.
Oct 18, 2023 • 1h 20min
Oncology Today with Dr Neil Love: Key Presentations on Multiple Myeloma from Recent Major Oncology/Hematology Conferences
Dr Joseph Mikhael discusses updates in multiple myeloma management, including the concept of stopping treatment for patients with deep responses, the use of MRD negativity to determine treatment level, neurological toxicities associated with certain treatments, utilization of specific treatments in medical oncology offices, advantages of bertimide vs. lintalitamide, and the examination of a treatment for multiple myeloma.
